Symbols / SKYE $0.72 +8.39%
SKYE Chart
About
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 22.94M |
| Enterprise Value | -1.57M | Income | -55.92M | Sales | — |
| Book/sh | 0.60 | Cash/sh | 0.77 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -0.74 | PEG | — |
| P/S | — | P/B | 1.19 | P/C | — |
| EV/EBITDA | 0.03 | EV/Sales | — | Quick Ratio | 3.14 |
| Current Ratio | 3.30 | Debt/Eq | 1.37 | LT Debt/Eq | — |
| EPS (ttm) | -1.30 | EPS next Y | -0.97 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-07 | ROA | -71.93% |
| ROE | -126.85% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 32.06M |
| Shs Float | 21.20M | Short Float | 4.46% | Short Ratio | 3.31 |
| Short Interest | — | 52W High | 5.75 | 52W Low | 0.61 |
| Beta | 2.86 | Avg Volume | 703.51K | Volume | 374.18K |
| Target Price | $8.25 | Recom | Buy | Prev Close | $0.66 |
| Price | $0.72 | Change | 8.39% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.25
Mean price target
2. Current target
$0.72
Latest analyst target
3. DCF / Fair value
$-12.89
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.72
Low
$2.00
High
$20.00
Mean
$8.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-30 | init | HC Wainwright & Co. | — → Buy | $20 |
| 2025-08-15 | init | Evercore ISI Group | — → Outperform | $10 |
| 2025-06-24 | reit | JMP Securities | Market Outperform → Market Outperform | $15 |
| 2025-03-21 | main | Craig-Hallum | Buy → Buy | $14 |
| 2025-03-21 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $15 |
| 2025-02-28 | init | William Blair | — → Outperform | — |
| 2024-09-30 | init | Scotiabank | — → Sector Outperform | $20 |
| 2024-09-20 | reit | Piper Sandler | Overweight → Overweight | $20 |
| 2024-09-20 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-09-10 | init | JMP Securities | — → Market Outperform | $15 |
| 2024-09-09 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-09-06 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-08-27 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-07-09 | init | Craig-Hallum | — → Buy | $18 |
| 2024-07-01 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-06-18 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-06-17 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-05-23 | init | Cantor Fitzgerald | — → Overweight | $21 |
| 2024-04-12 | init | Oppenheimer | — → Outperform | $25 |
| 2024-03-14 | reit | Piper Sandler | Overweight → Overweight | $20 |
- Skye obesity drug combo shows 22.3% loss, over 50% less regain - Stock Titan ue, 10 Mar 2026 20
- Cantor Fitzgerald reiterates Skye Bioscience stock rating at Neutral - Investing.com Wed, 11 Mar 2026 12
- SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal - Yahoo Finance ue, 07 Oct 2025 07
- Skye shares crash as obesity drug falls short in key study - BioPharma Dive Mon, 06 Oct 2025 07
- Skye’s shares crash down to earth on Phase II obesity loss - Clinical Trials Arena ue, 07 Oct 2025 07
- Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire ue, 10 Mar 2026 20
- $SKYE stock is down 56% today. Here's what we see in our data. - Quiver Quantitative Mon, 06 Oct 2025 07
- Citizens reiterates Skye Bioscience stock rating on weight loss data - Investing.com Wed, 11 Mar 2026 10
- CFO exits Skye Bioscience (SKYE) with $450k severance; CEO takes accounting duties - Stock Titan Fri, 20 Feb 2026 08
- Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 - GlobeNewswire hu, 05 Mar 2026 12
- Skye Bioscience to Present Research on Nimacimab at Keystone Conference on Obesity Therapeutics - Quiver Quantitative Wed, 21 Jan 2026 08
- Companies Like Skye Bioscience (NASDAQ:SKYE) Could Be Quite Risky - Yahoo Finance Mon, 12 Jan 2026 08
- Biotechs team up to test higher-dose obesity shots in mid-2026 trial - Stock Titan Mon, 05 Jan 2026 08
- Skye Bioscience stock plummets after failed weight loss drug trial - Investing.com Mon, 06 Oct 2025 07
- A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience - Yahoo Finance Wed, 07 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 231405 | 800548 | — | Sale at price 3.42 - 3.57 per share. | SCHWAB ANDREW J. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-08-22 00:00:00 | I |
| 1 | 231405 | 800548 | — | Sale at price 3.42 - 3.57 per share. | 5AM PARTNERS VII, LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-08-22 00:00:00 | I |
| 2 | 86551 | 432061 | — | Sale at price 4.99 - 5.55 per share. | GRAYSON PAUL A. | Director | — | 2024-11-18 00:00:00 | D |
| 3 | 82910 | 413925 | — | Sale at price 4.99 - 5.55 per share. | DHILLON PUNIT S | Chief Executive Officer | — | 2024-11-18 00:00:00 | D |
| 4 | 43396 | 216652 | — | Sale at price 4.99 - 5.55 per share. | ARSENAULT KAITLYN MELANIE | Chief Financial Officer | — | 2024-11-18 00:00:00 | D |
| 5 | 43216 | 215754 | — | Sale at price 4.99 - 5.55 per share. | ARSENAULT KAITLYN MELANIE | Chief Financial Officer | — | 2024-11-18 00:00:00 | D |
| 6 | 19574 | 97722 | — | Sale at price 4.99 - 5.55 per share. | DIEP TUAN TU | Officer | — | 2024-11-18 00:00:00 | D |
| 7 | 266337 | 1750352 | — | Sale at price 6.06 - 6.60 per share. | SCHWAB ANDREW J. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-09-13 00:00:00 | I |
| 8 | 266337 | 1750352 | — | Sale at price 6.06 - 6.60 per share. | 5AM PARTNERS VII, LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2024-09-13 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 1.59M | -4.57M | -1.39M | 26.13K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -32.88M | -14.84M | -12.09M | -7.82M |
| TotalUnusualItems | 7.59M | -21.78M | -6.60M | 96.79K |
| TotalUnusualItemsExcludingGoodwill | 7.59M | -21.78M | -6.60M | 96.79K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -26.57M | -37.64M | -19.48M | -8.52M |
| ReconciledDepreciation | 298.64K | 124.25K | 115.00K | 34.13K |
| EBITDA | -25.29M | -36.62M | -18.70M | -7.72M |
| EBIT | -25.59M | -36.74M | -18.81M | -7.75M |
| NetInterestIncome | 2.28M | -806.30K | -766.35K | -769.16K |
| InterestExpense | 967.60K | 897.21K | 663.77K | 767.51K |
| InterestIncome | 3.26M | 99.97K | 19.01K | 3.00 |
| NormalizedIncome | -32.57M | -20.44M | -14.27M | -8.59M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -26.57M | -37.64M | -19.48M | -8.52M |
| TotalExpenses | 36.43M | 13.67M | 12.11M | 7.85M |
| TotalOperatingIncomeAsReported | -30.19M | -34.74M | -18.31M | -7.85M |
| DilutedAverageShares | 36.49M | 7.01M | 2.22M | 1.63M |
| BasicAverageShares | 36.49M | 7.01M | 2.22M | 1.63M |
| DilutedEPS | -0.73 | -5.37 | -8.77 | -5.00 |
| BasicEPS | -0.73 | -5.37 | -8.77 | -5.00 |
| DilutedNIAvailtoComStockholders | -26.57M | -37.64M | -19.48M | -8.52M |
| NetIncomeCommonStockholders | -26.57M | -37.64M | -19.48M | -8.52M |
| NetIncome | -26.57M | -37.64M | -19.48M | -8.52M |
| NetIncomeIncludingNoncontrollingInterests | -26.57M | -37.64M | -19.48M | -8.52M |
| NetIncomeContinuousOperations | -26.57M | -37.64M | -19.48M | -8.52M |
| TaxProvision | 10.07K | 3.60K | 6.74K | 2.10K |
| PretaxIncome | -26.56M | -37.64M | -19.47M | -8.52M |
| OtherIncomeExpense | 7.59M | -23.16M | -6.60M | 96.79K |
| OtherNonOperatingIncomeExpenses | -2.20K | -1.38M | ||
| SpecialIncomeCharges | 7.59M | -21.78M | -6.66M | 117.95K |
| GainOnSaleOfPPE | 1.36M | -307.09K | 0.00 | |
| GainOnSaleOfBusiness | 0.00 | -409.35K | -456.51K | 0.00 |
| OtherSpecialCharges | -6.23M | 21.06M | 6.21M | -117.95K |
| WriteOff | 456.51K | 0.00 | ||
| RestructuringAndMergernAcquisition | 409.35K | 456.51K | 0.00 | |
| GainOnSaleOfSecurity | 3.00 | 59.73K | -21.16K | |
| NetNonOperatingInterestIncomeExpense | 2.28M | -806.30K | -766.35K | -769.16K |
| TotalOtherFinanceCost | 16.46K | 9.06K | 121.59K | 1.65K |
| InterestExpenseNonOperating | 967.60K | 897.21K | 663.77K | 767.51K |
| InterestIncomeNonOperating | 3.26M | 99.97K | 19.01K | 3.00 |
| OperatingIncome | -36.43M | -13.67M | -12.11M | -7.85M |
| OperatingExpense | 36.43M | 13.67M | 12.11M | 7.85M |
| ResearchAndDevelopment | 18.70M | 5.82M | 6.01M | 2.93M |
| SellingGeneralAndAdministration | 17.73M | 7.85M | 6.09M | 4.92M |
| GeneralAndAdministrativeExpense | 17.73M | 7.85M | 6.09M | 4.92M |
| OtherGandA | 17.73M | 7.85M | 6.09M | 4.92M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 30.97M | 12.35M | 3.65M | 1.90M |
| ShareIssued | 30.97M | 12.35M | 3.65M | 1.90M |
| NetDebt | 3.12M | 659.30K | ||
| TotalDebt | 455.59K | 4.62M | 1.98M | 2.14M |
| TangibleBookValue | 68.15M | -2.13M | -3.01M | 5.86M |
| InvestedCapital | 68.15M | 2.24M | -1.10M | 7.84M |
| WorkingCapital | 66.49M | -2.25M | -3.18M | 5.70M |
| NetTangibleAssets | 68.15M | -2.13M | -3.01M | 5.86M |
| CapitalLeaseObligations | 455.59K | 243.27K | 78.70K | 161.07K |
| CommonStockEquity | 68.15M | -2.13M | -3.01M | 5.86M |
| TotalCapitalization | 68.15M | -2.13M | -3.01M | 5.86M |
| TotalEquityGrossMinorityInterest | 68.15M | -2.13M | -3.01M | 5.86M |
| StockholdersEquity | 68.15M | -2.13M | -3.01M | 5.86M |
| RetainedEarnings | -130.95M | -104.38M | -66.74M | -47.26M |
| AdditionalPaidInCapital | 199.07M | 102.24M | 63.73M | 52.64M |
| CapitalStock | 30.98K | 12.35K | 3.65K | 476.11K |
| CommonStock | 30.98K | 12.35K | 3.65K | 476.11K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 4.61M | 14.07M | 12.12M | 3.99M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 273.16K | 171.23K | 0.00 | 78.70K |
| LongTermDebtAndCapitalLeaseObligation | 273.16K | 171.23K | 0.00 | 78.70K |
| LongTermCapitalLeaseObligation | 273.16K | 171.23K | 0.00 | 78.70K |
| CurrentLiabilities | 4.34M | 13.90M | 12.12M | 3.91M |
| OtherCurrentLiabilities | 549.15K | 969.62K | 7.48M | 435.57K |
| CurrentDebtAndCapitalLeaseObligation | 182.43K | 4.44M | 1.98M | 2.06M |
| CurrentCapitalLeaseObligation | 182.43K | 72.04K | 78.70K | 82.37K |
| CurrentDebt | 4.37M | 1.90M | 1.97M | |
| OtherCurrentBorrowings | 4.37M | 1.90M | 1.97M | |
| PayablesAndAccruedExpenses | 3.61M | 8.49M | 2.65M | 1.42M |
| CurrentAccruedExpenses | 3.04M | 7.53M | 763.00K | 519.36K |
| InterestPayable | 0.00 | 360.78K | 15.81K | 174.91K |
| Payables | 569.25K | 956.75K | 1.89M | 900.01K |
| OtherPayable | 55.45K | |||
| DuetoRelatedPartiesCurrent | 0.00 | 95.85K | 0.00 | |
| AccountsPayable | 569.25K | 956.75K | 1.79M | 900.01K |
| TotalAssets | 72.76M | 11.94M | 9.11M | 9.86M |
| TotalNonCurrentAssets | 1.94M | 289.57K | 167.35K | 242.99K |
| OtherNonCurrentAssets | 53.91K | 8.31K | 8.31K | 8.31K |
| NetPPE | 1.88M | 281.26K | 159.04K | 234.68K |
| AccumulatedDepreciation | -233.51K | -95.43K | ||
| GrossPPE | 2.12M | 376.69K | 159.04K | 234.68K |
| Leases | 23.92K | 13.95K | ||
| OtherProperties | 449.86K | 237.98K | 71.19K | 146.97K |
| MachineryFurnitureEquipment | 1.64M | 124.76K | ||
| BuildingsAndImprovements | 43.28K | 87.85K | 87.71K | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 70.83M | 11.65M | 8.94M | 9.61M |
| OtherCurrentAssets | 207.21K | 558.25K | 306.08K | 56.87K |
| AssetsHeldForSaleCurrent | 0.00 | 6.43M | 0.00 | |
| RestrictedCash | 0.00 | 9.08M | 4.58K | 4.57K |
| PrepaidAssets | 2.20M | 597.70K | 882.19K | 567.65K |
| Receivables | 5.07K | 158.24K | 74.12K | |
| TaxesReceivable | 5.07K | 158.24K | 74.12K | |
| CashCashEquivalentsAndShortTermInvestments | 68.42M | 1.26M | 1.24M | 8.98M |
| CashAndCashEquivalents | 68.42M | 1.26M | 1.24M | 8.98M |
| CashFinancial | 1.26M | 1.24M | 8.98M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -26.84M | -13.96M | -12.77M | -6.57M |
| RepaymentOfDebt | 0.00 | -259.33K | -891.66K | 0.00 |
| IssuanceOfDebt | 0.00 | 4.97M | 680.90K | 0.00 |
| IssuanceOfCapitalStock | 83.56M | 11.73M | 0.00 | 6.06M |
| CapitalExpenditure | -1.60M | -12.55K | -28.06K | -90.87K |
| InterestPaidSupplementalData | 433.34K | 198.35K | 333.55K | 44.09K |
| IncomeTaxPaidSupplementalData | 5.20K | 3.60K | 6.74K | 1.60K |
| EndCashPosition | 68.42M | 10.34M | 1.25M | 8.99M |
| BeginningCashPosition | 10.34M | 1.25M | 8.99M | 2.47M |
| ChangesInCash | 58.08M | 9.09M | -7.74M | 6.51M |
| FinancingCashFlow | 83.56M | 16.44M | -208.79K | 13.08M |
| CashFlowFromContinuingFinancingActivities | 83.56M | 16.44M | -208.79K | 13.08M |
| NetOtherFinancingCharges | -6.03K | |||
| ProceedsFromStockOptionExercised | 5.62K | 0.00 | 1.97K | 7.02M |
| NetCommonStockIssuance | 83.56M | 11.73M | 0.00 | 6.06M |
| CommonStockIssuance | 83.56M | 11.73M | 0.00 | 6.06M |
| NetIssuancePaymentsOfDebt | 0.00 | 4.71M | -210.76K | 0.00 |
| NetShortTermDebtIssuance | 0.00 | 4.97M | 0.00 | 0.00 |
| ShortTermDebtPayments | -6.03K | -616.12K | 0.00 | |
| ShortTermDebtIssuance | 0.00 | 4.97M | 0.00 | |
| NetLongTermDebtIssuance | 0.00 | -259.33K | -210.76K | 0.00 |
| LongTermDebtPayments | 0.00 | -259.33K | -891.66K | 0.00 |
| LongTermDebtIssuance | 0.00 | 680.90K | 0.00 | |
| InvestingCashFlow | -245.62K | 6.60M | 5.21M | -90.87K |
| CashFlowFromContinuingInvestingActivities | -245.62K | 6.60M | 5.21M | -90.87K |
| NetOtherInvestingChanges | 1.08M | 5.24M | ||
| NetPPEPurchaseAndSale | -245.62K | 5.52M | -28.06K | -90.87K |
| SaleOfPPE | 1.36M | 5.53M | 0.00 | |
| PurchaseOfPPE | -1.60M | -12.55K | -28.06K | -90.87K |
| OperatingCashFlow | -25.24M | -13.95M | -12.74M | -6.47M |
| CashFlowFromContinuingOperatingActivities | -25.24M | -13.95M | -12.74M | -6.47M |
| ChangeInWorkingCapital | -2.63M | -469.31K | -761.90K | 646.94K |
| ChangeInOtherWorkingCapital | -8.31K | |||
| ChangeInOtherCurrentLiabilities | -438.79K | -665.89K | -1.83M | 157.00K |
| ChangeInOtherCurrentAssets | -1.46M | -488.79K | 112.91K | -64.90K |
| ChangeInPayablesAndAccruedExpense | -721.44K | -109.86K | 953.93K | 932.37K |
| ChangeInAccruedExpense | -134.90K | 591.42K | 154.19K | 413.73K |
| ChangeInInterestPayable | -360.78K | 360.78K | -159.10K | 130.82K |
| ChangeInPayable | -586.53K | -701.28K | 799.74K | 518.64K |
| ChangeInAccountPayable | -586.53K | -701.28K | 799.74K | 518.64K |
| ChangeInPrepaidAssets | -7.70K | 795.23K | -2.96K | -377.51K |
| OtherNonCashItems | -3.64M | 1.58M | 6.82M | 593.80K |
| StockBasedCompensation | 8.32M | 987.51K | 629.03K | 869.21K |
| AssetImpairmentCharge | 325.61K | 0.00 | ||
| DepreciationAmortizationDepletion | 298.64K | 124.25K | 115.00K | 34.13K |
| DepreciationAndAmortization | 298.64K | 124.25K | 115.00K | 34.13K |
| OperatingGainsLosses | -1.35M | 21.47M | -59.73K | -96.79K |
| GainLossOnInvestmentSecurities | -3.00 | -59.73K | 21.16K | |
| NetForeignCurrencyExchangeGainLoss | 0.00 | -45.35K | 0.00 | |
| GainLossOnSaleOfPPE | 0.00 | 21.22M | 0.00 | |
| NetIncomeFromContinuingOperations | -26.57M | -37.64M | -19.48M | -8.52M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SKYE
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|